Understanding why genitourinary cancers resist treatment
Molecular origins and evolution to treatment resistance in genitourinary cancers
This study is looking into why some people with prostate, bladder, kidney, and testicular cancers don’t respond to treatments, with the goal of finding better ways to help patients get the right therapies that work for them.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10886741 on NIH RePORTER |
What this research studies
This research investigates the molecular origins and evolution of treatment resistance in genitourinary cancers, including prostate, bladder, kidney, and testes cancers. By utilizing integrative computational and molecular approaches, the study aims to uncover the biological mechanisms behind why some patients do not respond to therapies. The research is grounded in the patient experience, focusing on developing new drug discovery paradigms and improving patient stratification for better treatment outcomes. The team also explores the interactions between tumors, the immune system, and genetic factors that contribute to treatment resistance.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients diagnosed with advanced genitourinary cancers who are experiencing treatment resistance.
Not a fit: Patients with early-stage genitourinary cancers or those who have not yet undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with genitourinary cancers by overcoming resistance to existing therapies.
How similar studies have performed: Other research has shown success in understanding treatment resistance in cancers, making this approach both relevant and promising.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Park, Jihye — Dana-Farber Cancer Inst
- Study coordinator: Park, Jihye
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.